Ulcerative Colitis
The clinical study is evaluating an oral investigational drug to see if it reduces the signs and symptoms of moderately to severely active ulcerative colitis by blocking certain processes involved in the inflammation pathway.
Study site: Encore Medical Research
- Ulcerative colitis (UC)
- About the Study
- The study aims to assess an oral investigational drug's effectiveness in reducing signs and symptoms of moderately to severely active ulcerative colitis by targeting specific processes in the inflammation pathway. Additionally, the study examines any potential adverse events or safety concerns related to the investigational drug, which is taken once a day as one to three tablets.
- What does the study involve?
- This study involves a randomized, double-blinded, placebo-controlled trial, where participants are assigned either the investigational drug or a placebo without knowing which. Participation can last 12 to 64 weeks, with an option to continue the investigational drug after the initial 12 weeks. Current medications may be continued alongside the investigational drug, subject to evaluation by the study doctor. For more details, contact the study site.
- Who can participate?
- Those eligible to participate are individuals currently experiencing symptoms such as diarrhea (with or without blood), stool urgency, or stool incontinence. Additionally, they must have received a diagnosis of ulcerative colitis and be between the ages of 18 and 75.
- Is compensation provided?
- Yes: $1+ for taking part.
Where is the study taking place?
Hollywood
Weston
Study details
Full record on ClinicalTrials.gov (NCT06029972)Study details are from ClinicalTrials.gov. The rest of this page is written by the study site for patients and may summarize or reword the registry record, which is the official text. A study listed on ClinicalTrials.gov has not necessarily been reviewed or approved by the U.S. government.
About Encore Medical Research
Encore Medical Research has been serving the South Florida Community since 2017 focusing on phases II through IV clinical trials. Our goal is to provide the highest standard of care to our patients while delivering unmatched performance in our research operations.